These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15199495)

  • 21. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coagulation testing in pediatric patients: the young are not just miniature adults.
    Lippi G; Franchini M; Montagnana M; Guidi GC
    Semin Thromb Hemost; 2007 Nov; 33(8):816-20. PubMed ID: 18175287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes.
    Corrao G; Zambon A; Nicotra F; Fornari C; La Vecchia C; Mezzanzanica M; Nappi RE; Merlino L; Cesana G
    Maturitas; 2007 Jul; 57(3):315-24. PubMed ID: 17485182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Present position of the hormonal replacement therapy].
    Fait T; Vokrouhlická J; Vrablík M; Jenícek J
    Cas Lek Cesk; 2004; 143(7):447-52. PubMed ID: 15373286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular health and the menopause: the gynecologist as the patients' interface.
    Arias RD
    Climacteric; 2006 Sep; 9 Suppl 1():6-12. PubMed ID: 16899438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemostatic factors according to menopausal status and use of hormone replacement therapy.
    Meilahn EN; Kuller LH; Matthews KA; Kiss JE
    Ann Epidemiol; 1992 Jul; 2(4):445-55. PubMed ID: 1342295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Right or wrong of the hormone replacement therapy involving osteoporosis].
    Hoshino S; Ouchi Y
    Clin Calcium; 2004 Nov; 14(11):87-98. PubMed ID: 15577164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone replacement therapy and cardiovascular disease revisited.
    Stevenson JC
    Menopause Int; 2009 Jun; 15(2):55-7. PubMed ID: 19465669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M; Vacca F
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
    Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
    Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
    Maffei S; Mercuri A; Prontera C; Zucchelli GC; Vassalle C
    Climacteric; 2006 Dec; 9(6):452-8. PubMed ID: 17085378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inventory of exogenous hemostatic factors affecting the prothrombin activating pathways. For the Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
    Stocker K
    Thromb Haemost; 1994 Feb; 71(2):257-60. PubMed ID: 8191409
    [No Abstract]   [Full Text] [Related]  

  • 36. Review article: coagulation disorders in chronic liver disease.
    Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2007 Nov; 26 Suppl 1():21-8. PubMed ID: 17958516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hormone treatment on hemostasis variables.
    Kluft C
    Climacteric; 2007 Oct; 10 Suppl 2():32-7. PubMed ID: 17882670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone replacement therapy and cardiovascular disease.
    Seed M
    Curr Opin Lipidol; 1999 Dec; 10(6):581-7. PubMed ID: 10680052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.